RVMD
Revolution Medicines, Inc. NASDAQ Listed Feb 13, 2020$178.17
After hrs
$178.17
+0.00%
Mkt Cap $37.9B
52w Low $34.00
95.9% of range
52w High $184.39
50d MA $150.02
200d MA $97.11
P/E (TTM)
—
EV/EBITDA
—
P/B
20.8x
Debt/Equity
0.1x
ROE
-69.3%
P/FCF
-35.3x
RSI (14)
64.80
ATR (14)
$5.84
Beta
1.01
50d MA
$150.02
200d MA
$97.11
Avg Volume
2.8M
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
700 Saginaw Drive · Redwood City, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -1.83 | -2.29 | -25.1% | 151.07 | -1.5% | -5.7% | -0.5% | +1.7% | +1.1% | +2.9% | — |
| Feb 25, 2026 | AMC | -1.58 | -1.86 | -17.7% | 103.24 | -7.5% | -1.1% | -0.1% | -0.4% | -1.1% | +0.7% | — |
| Nov 5, 2025 | AMC | -1.42 | -1.61 | -13.4% | 59.34 | +0.7% | +3.4% | -0.6% | +2.8% | +2.2% | +2.7% | — |
| Aug 6, 2025 | AMC | -0.94 | -1.31 | -39.4% | 36.67 | -6.8% | -4.7% | +0.1% | -0.9% | +1.6% | +2.3% | — |
| May 7, 2025 | AMC | -1.12 | -1.13 | -0.9% | 37.66 | +8.3% | +11.3% | -3.6% | +3.6% | -4.6% | -1.2% | — |
| Feb 26, 2025 | AMC | -1.01 | -1.12 | -10.9% | 40.50 | -1.5% | -3.5% | +4.2% | -5.9% | -1.0% | +4.4% | — |
| Nov 6, 2024 | AMC | -0.89 | -0.94 | -5.2% | 59.42 | -2.4% | -0.5% | +2.3% | +0.3% | -2.1% | -2.0% | — |
| Aug 7, 2024 | AMC | -0.77 | -0.81 | -5.2% | 42.27 | -5.1% | -0.7% | +2.2% | +0.2% | +0.0% | -1.0% | — |
| May 8, 2024 | AMC | -0.75 | -0.70 | +6.2% | 38.31 | +2.5% | -2.2% | -0.5% | -0.2% | +0.6% | +5.4% | — |
| Feb 26, 2024 | AMC | -0.86 | -1.14 | -32.6% | 30.38 | +4.1% | +0.8% | -2.2% | -1.6% | +1.1% | -1.0% | — |
| Nov 6, 2023 | AMC | -1.01 | -0.99 | +2.0% | 21.54 | -0.9% | -0.2% | -1.4% | -5.5% | -1.5% | -0.3% | — |
| Aug 8, 2023 | AMC | -0.83 | -0.92 | -10.8% | 30.17 | -1.0% | -1.8% | +0.6% | +0.6% | +0.0% | +2.3% | — |
| May 8, 2023 | AMC | -0.84 | -0.72 | +14.3% | 24.44 | -1.1% | +3.1% | -0.2% | +1.9% | +1.0% | +2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 22 | Bernstein | Initiates | Mkt Perform | $151 | $153.73 | $154.42 | +0.4% | -1.4% | +2.2% | -1.2% | +1.1% | +1.8% |
| May 18 | Truist | Reiterates | Buy | $179 | $145.66 | $145.03 | -0.4% | -0.9% | +2.0% | +2.1% | +2.3% | -1.4% |
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $148.90 | $149.67 | +0.5% | -5.0% | -5.0% | +0.6% | -2.7% | +10.0% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $148.90 | $149.67 | +0.5% | -5.0% | -5.0% | +0.6% | -2.7% | +10.0% |
| Apr 20 | Needham | Maintains | Buy → Buy | — | $148.63 | $151.85 | +2.2% | -1.6% | +1.8% | -5.0% | -5.0% | +0.6% |
| Apr 20 | Stifel | Maintains | Buy → Buy | — | $148.63 | $151.85 | +2.2% | -1.6% | +1.8% | -5.0% | -5.0% | +0.6% |
| Apr 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $136.30 | $136.50 | +0.1% | +7.9% | +3.8% | -2.1% | -0.4% | -1.6% |
| Apr 14 | Wedbush | Maintains | Outperform → Outperform | — | $136.30 | $136.50 | +0.1% | +7.9% | +3.8% | -2.1% | -0.4% | -1.6% |
| Apr 14 | Evercore ISI | Maintains | Outperform → Outperform | — | $136.30 | $136.50 | +0.1% | +7.9% | +3.8% | -2.1% | -0.4% | -1.6% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $136.30 | $136.50 | +0.1% | +7.9% | +3.8% | -2.1% | -0.4% | -1.6% |
| Apr 14 | RBC Capital | Maintains | Outperform → Outperform | — | $136.30 | $136.50 | +0.1% | +7.9% | +3.8% | -2.1% | -0.4% | -1.6% |
| Apr 14 | Guggenheim | Maintains | Buy → Buy | — | $136.30 | $136.50 | +0.1% | +7.9% | +3.8% | -2.1% | -0.4% | -1.6% |
| Apr 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $96.43 | $132.26 | +37.2% | +41.3% | +7.9% | +3.8% | -2.1% | -0.4% |
| Apr 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $96.43 | $132.26 | +37.2% | +41.3% | +7.9% | +3.8% | -2.1% | -0.4% |
| Feb 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $103.24 | $95.47 | -7.5% | -1.1% | -0.1% | -0.4% | -1.1% | +0.7% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $103.24 | $95.47 | -7.5% | -1.1% | -0.1% | -0.4% | -1.1% | +0.7% |
| Feb 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $103.24 | $95.47 | -7.5% | -1.1% | -0.1% | -0.4% | -1.1% | +0.7% |
| Feb 2 | JP Morgan | Maintains | Overweight → Overweight | — | $96.95 | $96.52 | -0.4% | +0.2% | -1.2% | +0.6% | -0.4% | +1.4% |
| Jan 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $97.78 | $98.14 | +0.4% | +2.1% | -2.5% | +0.9% | -1.3% | +0.2% |
| Jan 22 | Stifel | Maintains | Buy → Buy | — | $117.53 | $118.37 | +0.7% | +1.1% | -1.0% | -16.9% | +2.1% | -2.5% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $116.22 | $115.60 | -0.5% | +1.1% | +1.1% | -1.0% | -16.9% | +2.1% |
| Jan 20 | Guggenheim | Maintains | Buy → Buy | — | $120.28 | $118.59 | -1.4% | -3.4% | +1.1% | +1.1% | -1.0% | -16.9% |
| Jan 13 | Mizuho | Maintains | Outperform → Outperform | — | $117.17 | $118.16 | +0.8% | +2.4% | +1.1% | +1.7% | -2.4% | -3.4% |
| Jan 9 | Wedbush | Maintains | Outperform → Outperform | — | $107.39 | $120.00 | +11.7% | +10.5% | -1.2% | +2.4% | +1.1% | +1.7% |
| Nov 6 | Wedbush | Maintains | Outperform → Outperform | — | $59.34 | $59.73 | +0.7% | +3.4% | -0.6% | +2.8% | +2.2% | +2.7% |
| Nov 6 | JP Morgan | Maintains | Overweight → Overweight | — | $59.34 | $59.73 | +0.7% | +3.4% | -0.6% | +2.8% | +2.2% | +2.7% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $59.34 | $59.73 | +0.7% | +3.4% | -0.6% | +2.8% | +2.2% | +2.7% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.34 | $59.73 | +0.7% | +3.4% | -0.6% | +2.8% | +2.2% | +2.7% |
| Oct 17 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $49.68 | $52.76 | +6.2% | +8.9% | -0.2% | -1.0% | -1.0% | +0.9% |
| Oct 17 | Wedbush | Maintains | Outperform → Outperform | — | $49.68 | $52.76 | +6.2% | +8.9% | -0.2% | -1.0% | -1.0% | +0.9% |
| Sep 25 | JP Morgan | Maintains | Overweight → Overweight | — | $43.54 | $43.12 | -1.0% | -2.4% | +3.3% | +4.9% | +1.4% | -1.8% |
| Sep 12 | Goldman Sachs | Maintains | Buy → Buy | — | $46.24 | $46.80 | +1.2% | +0.7% | -0.8% | -3.2% | -2.0% | +3.2% |
| Sep 11 | Needham | Maintains | Buy → Buy | — | $40.45 | $42.90 | +6.1% | +14.3% | +0.7% | -0.8% | -3.2% | -2.0% |
| Sep 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $40.45 | $42.90 | +6.1% | +14.3% | +0.7% | -0.8% | -3.2% | -2.0% |
| Sep 11 | Wedbush | Maintains | Outperform → Outperform | — | $40.45 | $42.90 | +6.1% | +14.3% | +0.7% | -0.8% | -3.2% | -2.0% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $36.67 | $34.18 | -6.8% | -4.7% | +0.1% | -0.9% | +1.6% | +2.3% |
| Jun 25 | Guggenheim | Maintains | Buy → Buy | — | $40.03 | $40.17 | +0.3% | -4.0% | -2.4% | -1.5% | -0.3% | +0.3% |
| Jun 24 | Needham | Maintains | Buy → Buy | — | $40.04 | $38.45 | -4.0% | -0.0% | -4.0% | -2.4% | -1.5% | -0.3% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.95 | $39.70 | -0.6% | -1.2% | -0.1% | +0.3% | +1.0% | +1.4% |
| May 8 | Guggenheim | Maintains | Buy → Buy | — | $37.66 | $40.77 | +8.3% | +11.3% | -3.6% | +3.6% | -4.6% | -1.2% |
| May 8 | Needham | Maintains | Buy → Buy | — | $37.66 | $40.77 | +8.3% | +11.3% | -3.6% | +3.6% | -4.6% | -1.2% |
| May 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $37.66 | $40.77 | +8.3% | +11.3% | -3.6% | +3.6% | -4.6% | -1.2% |
| Apr 28 | Wedbush | Maintains | Outperform → Outperform | — | $38.77 | $38.96 | +0.5% | +7.0% | -1.9% | -0.7% | +0.6% | +0.2% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $31.40 | $32.29 | +2.8% | -0.9% | +12.8% | -4.1% | +6.1% | +2.1% |
| Apr 1 | Stifel | Maintains | Buy → Buy | — | $35.36 | $35.35 | -0.0% | -4.9% | +2.9% | -5.0% | -4.7% | +0.3% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.74 | $40.90 | +0.4% | -5.9% | -1.0% | +4.4% | -1.0% | -0.0% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $40.50 | $39.90 | -1.5% | -3.5% | +4.2% | -5.9% | -1.0% | +4.4% |
| Feb 27 | Stifel | Maintains | Buy → Buy | — | $40.50 | $39.90 | -1.5% | -3.5% | +4.2% | -5.9% | -1.0% | +4.4% |
| Jan 8 | UBS | Maintains | Buy → Buy | — | $44.33 | $44.45 | +0.3% | +0.2% | -5.9% | +1.9% | -6.4% | +0.3% |
| Dec 6 | Wedbush | Maintains | Outperform → Outperform | — | $47.30 | $47.26 | -0.1% | +1.6% | -2.1% | +0.5% | -1.8% | -3.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 29,600 | $160.12 | $4.7M | 154,647 | +3.31% | — |
| Jun 16, 2026 | Kelsey Stephen Michael | See Remarks | Sell | 4,175 | $156.12 | $652K | 291,876 | +1.73% | — |
| Jun 16, 2026 | Anders Jack | Chief Financial Officer | Sell | 2,722 | $156.12 | $425K | 123,269 | +1.73% | — |
| Jun 16, 2026 | Cislini Jeff | General Counsel | Sell | 2,157 | $156.12 | $337K | 56,521 | +1.73% | — |
| Jun 16, 2026 | GOLDSMITH MARK A | See Remarks | Sell | 10,020 | $156.12 | $1.6M | 267,330 | +1.73% | — |
| Jun 16, 2026 | Mancini Anthony | See Remarks | Sell | 4,615 | $156.12 | $720K | 49,975 | +1.73% | — |
| Jun 15, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 60,400 | $160.17 | $9.7M | 158,222 | +3.31% | — |
| Jun 11, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 200 | $150.17 | $30K | 158,222 | -2.17% | +2.23% |
| Jun 11, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 4,600 | $149.64 | $688K | 158,422 | -2.17% | +2.23% |
| Jun 11, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 1,800 | $148.72 | $268K | 163,022 | -2.17% | +2.23% |
| Jun 11, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 500 | $147.27 | $74K | 164,822 | -2.17% | +2.23% |
| Jun 11, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 700 | $146.04 | $102K | 165,322 | -2.17% | +2.23% |
| Jun 11, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 885 | $145.15 | $128K | 166,022 | -2.17% | +2.23% |
| Jun 11, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 1,315 | $144.28 | $190K | 166,907 | -2.17% | +2.23% |
| May 26, 2026 | Mancini Anthony | See Remarks | Sell | 421 | $154.82 | $65K | 54,400 | +1.84% | -0.19% |
| May 26, 2026 | Mancini Anthony | See Remarks | Sell | 2,000 | $154.06 | $308K | 54,821 | +1.84% | -0.19% |
| May 26, 2026 | Mancini Anthony | See Remarks | Sell | 700 | $153.30 | $107K | 56,821 | +1.84% | -0.19% |
| Apr 27, 2026 | Mancini Anthony | See Remarks | Sell | 400 | $134.34 | $54K | 54,400 | +2.54% | +2.62% |
| Apr 27, 2026 | Mancini Anthony | See Remarks | Sell | 1,049 | $132.88 | $139K | 54,800 | +2.54% | +2.62% |
| Apr 27, 2026 | Mancini Anthony | See Remarks | Sell | 1,671 | $131.66 | $220K | 55,849 | +2.54% | +2.62% |
| Jun 16, 2025 | Horn Margaret A | Chief Operating Officer | Sell | 3,575 | $156.12 | $558K | 154,647 | +3.31% | — |
8-K
Revolution Medicines, Inc. -- 8-K Filing
Jun 22
8-K · 7.01
! Medium
Tango Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Tango Therapeutics announced positive Phase 1/2 safety and efficacy data for vopimetostat combined with Revolution Medicines' RAS inhibitors, potentially validating the combination approach for future development.
Jun 8
8-K · 1.01
! Medium
Revolution Medicines, Inc. -- 8-K 1.01: Underwriting / Securities
Revolution Medicines issued convertible notes on April 17, 2026, with U.S. Bank Trust Company as trustee, providing the company with capital funding while offering investors conversion rights into equity.
Apr 17
8-K
Unknown — 8-K Filing
RVMD completed an equity underwriting with standard indemnification provisions, indicating a secondary offering that will dilute existing shareholders while providing capital for operations or strategic initiatives.
Apr 16
8-K
Unknown — 8-K Filing
Revmed's daraxonrasib advancement toward regulatory submission offers potential upside if efficacy data proves compelling, but substantial development risks mean stock performance heavily depends on upcoming clinical results.
Apr 13
8-K
Unknown — 8-K Filing
Revolution Medicines secured up to $1 billion in non-dilutive financing tied to daraxonrasib's FDA approval milestones, reducing capital needs while Royalty Pharma gains royalty upside if the drug achieves blockbuster sales.
Apr 13
8-K
Revolution Medicines, Inc. -- 8-K Filing
Revolution Medicines reported 2025 full-year financial results and corporate updates, with the late-stage oncology company continuing development of targeted RAS-cancer therapies.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Farallon Capital Management Llc | 13,604,796 | $1.3B | New | Mar 2026 |
| 2 | Janus Henderson Group Plc | 9,766,496 | $950M | New | Mar 2026 |
| 3 | Fmr Llc | 8,464,314 | $823M | Reduced | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 8,362,284 | $813M | New | Mar 2026 |
| 5 | Vanguard Portfolio Management Llc | 7,502,623 | $730M | New | Mar 2026 |
| 6 | Ubs Group Ag | 4,386,791 | $427M | Added | Mar 2026 |
| 7 | Alphabet Inc. | 3,345,102 | $266M | Reduced | Dec 2025 |
| 8 | Woodline Partners Lp | 2,506,570 | $244M | — | Mar 2026 |
| 9 | Avoro Capital Advisors Llc | 2,344,444 | $228M | Added | Mar 2026 |
| 10 | Deerfield Management Company, L.p. | 2,297,000 | $223M | Reduced | Mar 2026 |
| 11 | Alyeska Investment Group, L.p. | 1,885,821 | $183M | Added | Mar 2026 |
| 12 | Two Sigma Investments, Lp | 1,558,807 | $152M | Added | Mar 2026 |
| 13 | Bellevue Group Ag | 1,544,456 | $150M | Reduced | Mar 2026 |
| 14 | Franklin Resources Inc | 1,133,546 | $110M | Added | Mar 2026 |
| 15 | Morgan Stanley | 1,303,464 | $104M | Reduced | Dec 2025 |
| 16 | D.e. Shaw & Co | 1,022,298 | $99M | Reduced | Mar 2026 |
| 17 | Northern Trust Corp | 954,256 | $93M | Added | Mar 2026 |
| 18 | Pictet Asset Management Holding Sa | 1,137,121 | $91M | Reduced | Dec 2025 |
| 19 | Jane Street Group, Llc | 1,090,416 | $87M | Added | Dec 2025 |
| 20 | Candriam S.c.a. | 1,030,992 | $82M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$37.88B
Enterprise Value
$30.39B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.20x
P/B
20.77x
P/S
—
P/FCF
-35.33x
EV/EBITDA
—
Shares Out
190.1M
Financials (TTM)
Revenue
$0
Net Income
-$1.37B
EBITDA
-$1.32B
Free Cash Flow
-$913.7M
Op Cash Flow
-$897.7M
EPS Basic
$-5.95
EPS Diluted
$-7.11
EPS Forward
$-7.55
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$2.35B
Total Liab.
$723.2M
Total Equity
$1.63B
Cash
$2.03B
LT Debt
$142.2M
Book Value/Sh
$8.58
Debt/Equity
0.10x
Current Ratio
7.14
Quick Ratio
7.14
Returns & Growth
ROE
-69.3%
ROA
-48.0%
ROIC
-56.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
-66.2%
Price Returns
2W
+5.4%
1M
+9.3%
3M
+54.4%
6M
+102.5%
12M
+299.7%
Technicals
52W High
$184.39
52W Low
$34.00
50d MA
$150.02
200d MA
$97.11
RSI (14)
64.80
ATR (14)
$5.84
Beta
1.01
Avg Volume
2.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$154.80
High
$200.00
Low
$73.00
Median
$163.50
Data updated apr 26, 2026 11:43pm
· Source: financialmodelingprep.com